Advertisement

October 2, 2019

CryoLife Enters Into Distribution Agreement With Endospan

October 2, 2019—CryoLife, Inc., an Israeli-based, privately held company, announced that it has entered into distribution and credit facility agreements with Endospan. Additionally, CryoLife has advised it has an option agreement to purchase Endospan, developer of the Nexus endovascular stent graft system. Nexus is approved for the repair of both aneurysms and dissections in the aortic arch.

The transaction adds Nexus to CryoLife’s branched aortic stent graft portfolio and will offer a more comprehensive and differentiated portfolio of products and technologies for the endovascular treatment of the entire aorta, from the ascending aorta to the iliac arteries.

According to CryoLife, Nexus is a branched endovascular system approved to treat aortic arch disease as a standard endovascular procedure. It is designed for enhanced intraprocedural and long-term stability attributable to its proprietary geometrical design, which reduces arch manipulation and, therefore, stroke risks.

In the company's announcement, Professor Nicolas Doll, MD, commented, “Nexus is a highly differentiated stent graft system that allows physicians to repair aneurysms and dissections in the aortic arch through an endovascular approach. Nexus is especially important for elderly patients who are not suited for open surgery, and for patients with a prior type A dissection that was repaired in an open surgical approach.”

Professor Hubert Schelzig, MD, added, “The Nexus system has the potential to cross the next frontier in aortic surgery, namely a safe, therapeutic, minimally invasive procedure in aortic arch pathology. Not only does it provide a platform to treat the aortic arch, but it is a perfect fit with CryoLife’s highly differentiated and comprehensive portfolio of products that treat the entire aorta.”

Advertisement


October 3, 2019

AngioDynamics Acquires Eximo Medical

October 2, 2019

RFPi Receives NIH Grant to Develop Novel Evaluation Tool for Asymptomatic Patients at Risk for PAD